{
    "root": "163c129d-f4e2-484d-af96-c265c9a5e38c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "Envarsus",
        "suffix": {
            "text": "XR"
        }
    },
    "value": "20250226",
    "ingredients": [
        {
            "name": "TACROLIMUS",
            "code": "WM0HAQ4WNM"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "POLYETHYLENE GLYCOL 6000",
            "code": "30IQX730WE"
        },
        {
            "name": "POLOXAMER 188",
            "code": "LQA7B6G8JG"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "TARTARIC ACID",
            "code": "W4888I119H"
        },
        {
            "name": "BUTYLATED HYDROXYTOLUENE",
            "code": "1P9D0Z171K"
        },
        {
            "name": "DIMETHICONE",
            "code": "92RU3N3Y1O"
        }
    ],
    "indications": "envarsus xr calcineurin-inhibitor immunosuppressant indicated : prophylaxis organ rejection de novo kidney transplant patients combination immunosuppressants ( 1.1 ) prophylaxis organ rejection kidney transplant patients converted tacrolimus immediate-release formulations combination immunosuppressants ( 1.2 )",
    "contraindications": "take daily empty stomach time day , preferably morning . ( 2.1 ) avoid eating grapefruit drinking grapefruit juice alcohol . ( 2.1 ) african-american patients may need titrated higher dosages achieve target tacrolimus concentrations . ( 2.4 ) patients severe hepatic impairment may require lower starting dose . ( 2.4 ) frequent monitoring trough concentrations recommended . ( 2.5 ) recommended envarsus xr initial initial oral whole blood trough concentration range de novo kidney transplantation antibody induction 0.14 mg/kg/day month 1 : 6-11 ng/ml > month 1 : 4-11 ng/ml conversion tacrolimus immediate-release formulations 80 % pre-conversion dose tacrolimus immediate-release titrate 4-11 ng/ml",
    "warningsAndPrecautions": "envarsus xr supplied round hdpe bottles twist-off caps ( table 12 ) ; statement \u2018 once-daily \u2019 appears labels . table 12. strengths envarsus xr strength description ndc 0.75 mg oval , white off-white uncoated extended-release tablet , debossed \u201c 0.75 \u201d one side \u201c tcs \u201d side . 30-count ( ndc 68992-3075-3 ) 100-count ( ndc 68992-3075-1 ) 1 mg oval , white off-white uncoated extended-release tablet , debossed \u201c 1 \u201d one side \u201c tcs \u201d side . 30-count ( ndc 68992-3010-3 ) 100-count ( ndc 68992-3010-1 ) 4 mg oval , white off-white uncoated extended-release tablet , debossed \u201c 4 \u201d one side \u201c tcs \u201d side . 30-count ( ndc 68992-3040-3 ) 100-count ( ndc 68992-3040-1 ) store dispense store 25 \u00b0c ( 77 \u00b0f ) ; excursions permitted 15 \u00b0c 30 \u00b0c ( 59 \u00b0f 86 \u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "envarsus xr contraindicated patients known hypersensitivity tacrolimus ingredients envarsus xr .",
    "indications_original": "ENVARSUS XR is a calcineurin-inhibitor immunosuppressant indicated for: The prophylaxis of organ rejection in de novo kidney transplant patients in combination with other immunosuppressants  ( 1.1 ) The prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations in combination with other immunosuppressants ( 1.2 )",
    "contraindications_original": "Take once daily on empty stomach at the same time of the day, preferably in the morning. ( 2.1 ) Avoid eating grapefruit or drinking grapefruit juice or alcohol. ( 2.1 ) African-American patients may need to be titrated to higher dosages to achieve the target tacrolimus concentrations. ( 2.4 ) Patients with severe hepatic impairment may require a lower starting dose. ( 2.4 ) Frequent monitoring of trough concentrations is recommended. ( 2.5 ) Recommended ENVARSUS XR Initial Dosage Initial Oral Dosage Whole Blood Trough Concentration Range De novo kidney transplantation with antibody induction 0.14 mg/kg/day Month 1: 6-11 ng/mL >Month 1: 4-11 ng/mL Conversion from tacrolimus immediate-release formulations 80% of the pre-conversion dose of tacrolimus immediate-release Titrate to 4-11 ng/mL",
    "warningsAndPrecautions_original": "ENVARSUS XR is supplied in round HDPE bottles with twist-off caps (see Table 12); the statement \u2018ONCE-DAILY\u2019 appears on its labels.\n                  \n                     Table 12. Strengths of ENVARSUS XR\n                     \n                     \n                     \n                     \n                        \n                           Strength\n                           Description\n                           NDC\n                        \n                        \n                           0.75 mg\n                           Oval, white to off-white uncoated extended-release tablet, debossed with \u201c0.75\u201d on one side and \u201cTCS\u201d on the other side.\n                           30-count (NDC 68992-3075-3) 100-count (NDC 68992-3075-1)\n                        \n                        \n                           1 mg\n                           Oval, white to off-white uncoated extended-release\ntablet, debossed with \u201c1\u201d on one side and \u201cTCS\u201d on the\nother side.\n                           30-count (NDC 68992-3010-3)100-count (NDC 68992-3010-1)\n                        \n                        \n                           4 mg\n                           Oval, white to off-white uncoated extended-release\ntablet, debossed with \u201c4\u201d on one side and \u201cTCS\u201d on the\nother side.\n                           30-count (NDC 68992-3040-3)100-count (NDC 68992-3040-1)\n                        \n                     \n                  \n                  \n                     Store and Dispense\n                     Store at 25 \u00b0C (77 \u00b0F); excursions permitted to 15 \u00b0C to 30 \u00b0C (59 \u00b0F to 86 \u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "ENVARSUS XR is contraindicated in patients with known hypersensitivity to tacrolimus or to any of the ingredients in ENVARSUS XR."
}